Serina Therapeutics Accelerates SER-252 Trial as Cash Position Swells
Event summary
- Completed enrollment and dosing in Cohort 1 of SER-252 Phase 1b trial ahead of schedule (July 2026).
- Top-line data from single-ascending-dose arm expected in first half of 2027.
- Appointed Farrell Simon, Pharm.D., to Board of Directors with commercial strategy expertise.
- Cash position surged to $23.0M as of June 30, 2026, up from $3.1M a year prior.
The big picture
Serina Therapeutics' progress in its SER-252 trial positions it as a contender in the Parkinson's disease treatment space, where continuous dopaminergic stimulation remains an unmet need. The company's proprietary POZ platform could differentiate its approach from competitors like Trevi Therapeutics if clinical data supports its claims of improved tolerability and pharmacokinetic profiles.
What we're watching
- Clinical Execution
- Whether the accelerated Cohort 1 completion will translate to smoother dose escalation and safety reviews.
- Financial Runway
- How the $23M cash position will support operations until potential 2027 data readouts or next funding round.
- Commercial Strategy
- The impact of Farrell Simon's appointment on out-licensing discussions for Serina's POZ platform technology.
Related topics